NCT00915681: A trial that was reported late by Mylan Specialty, LP
This trial has reported, although it was 143 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT00915681 |
|---|---|
| Title | A Phase II Multi-Center Open-Label Clinical Trial to Assess the Prevention of Liver Transplantation and/or Death Among Subjects Treated With Intravenous Silibinin (Legalon® SIL) for Amatoxin Induced Hepatic Failure |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Nov. 10, 2009 |
| Completion date | April 10, 2020 |
| Required reporting date | April 10, 2021, midnight |
| Actual reporting date | Aug. 31, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 143 |